SynthesisBritish journal of haematology2017

A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.

Jacob P Laubach et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.